ReviewProstate cancer and prostatic diseases2007
Androgen receptor and prostate cancer.
Review in Prostate cancer and prostatic diseases, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 76 citations in OpenAlex.
- Identification of A p300-SP1-BRD4 Transcriptional Axis as a Key Driver of AR Hyperactivation in Polycystic Ovarian Syndrome.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Review On the Effects Curcumin on Tumors of the Reproductive System: Curcumin and Reproductive Tumors.Galen medical journal · 2021Article
- Curcumin-Gene Expression Response in Hormone Dependent and Independent Metastatic Prostate Cancer Cells.International journal of molecular sciences · 2019Article
- Circulating tumor DNA in advanced prostate cancer: transitioning from discovery to a clinically implemented test.Prostate cancer and prostatic diseases · 2019Review
- The Genomics of Prostate Cancer: A Historic Perspective.Cold Spring Harbor perspectives in medicine · 2019Review
- A Tale of Two Signals: AR and WNT in Development and Tumorigenesis of Prostate and Mammary Gland.Cancers · 2017Review
- SH003 induces apoptosis of DU145 prostate cancer cells by inhibiting ERK-involved pathway.BMC complementary and alternative medicine · 2016Article
- Effect of curcumin on the interaction between androgen receptor and Wnt/β-catenin in LNCaP xenografts.Korean journal of urology · 2015Article
- Genome-wide analysis of androgen receptor binding sites in prostate cancer cells.Experimental and therapeutic medicine · 2015Article
- The interplay of AMP-activated protein kinase and androgen receptor in prostate cancer cells.Journal of cellular physiology · 2014Article
- Shikonin inhibits the growth of human prostate cancer cells via modulation of the androgen receptor.International journal of oncology · 2014Article
- Article
- Association of serum calcium with serum sex steroid hormones in men in NHANES III.The aging male : the official journal of the International Society for the Study of the Aging Male · 2013Article
- Characterization of tumor differentiation factor (TDF) and its receptor (TDF-R).Cellular and molecular life sciences : CMLS · 2013Review
- Proteomic analysis of microvesicles released by the human prostate cancer cell line PC-3.Molecular & cellular proteomics : MCP · 2012Article
- Oncogenic activation of ERG: A predominant mechanism in prostate cancer.Journal of carcinogenesis · 2011Article
- Tissue slice grafts: an in vivo model of human prostate androgen signaling.The American journal of pathology · 2010Article
- Expression analysis and study of the KLK15 mRNA splice variants in prostate cancer and benign prostatic hyperplasia.Cancer science · 2010Article
- Candidate pathways and genes for prostate cancer: a meta-analysis of gene expression data.BMC medical genomics · 2009Article
- Transcriptional repression and inhibition of nuclear translocation of androgen receptor by diallyl trisulfide in human prostate cancer cells.Clinical cancer research : an official journal of the American Association for Cancer Research · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since the original observations of Huggins and Hodges that prostate cancers are androgen dependent, androgen ablation therapy has been the gold standard for the treatment of advanced prostate cancer (CaP). Androgen receptor (AR) is believed to play critical roles in the development and progression of CaP. Treatment for neoadjuvant, adjuvant and recurrent disease all center on the regulation and manipulation of the androgen pathway, in which AR plays an integral role. Recent discoveries that frequent overexpression of ETS-related proto-oncogenes may be driven by AR as a consequence of common genomic rearrangements can hold the key towards the understanding of early phases of prostate cancer. Furthermore, AR function evolves as the cell changes towards a clinically androgen depletion independent state. Comprehension of AR function, regulation and abnormalities are increasingly refined towards the understanding of the role of AR in CaP, and in therapeutic applications. Development of future therapy for CaP will be aided by improving the knowledge of dysfunctions of AR and its network in prostate cancer. This review focuses salient features of AR and on the recent advances addressing AR dysfunctions in prostate cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.